Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis' obesity drug Acomplia is facing a demanding European safety assessment following the release of data which links the drug to suicidal thoughts.
Subscribe to our email newsletter
The European Medicines Agency (EMEA) is reviewing Acomplia a month after US regulators rejected the drug on the grounds that the drug’s benefits failed to outweigh side-affects, including suicidal thoughts and depression.
The company spent more than 10 years developing the drug.
In Europe, Acomplia has been on sale since last year. It is also marketed under the brand name Zimulti. European officials are expected to allow it to stay on the market, but with stricter warnings, Reuters said.